Targets IL-1β to control inflammation in autoinflammatory diseases.
IL-1β Blockade in Autoinflammatory and Gout Disorders

CAPS/TRAPS/HIDS/MKD/FMF: Rapid normalization of CRP/SAA, resolution of fever, rash, and pain. In CAPS, 97% achieved clinical response by Week 8.

Still’s Disease: Reduced arthritis, systemic inflammation (91% CRP reduction), and corticosteroid dependency.

Gout Flares: Superior pain reduction vs. triamcinolone at 72 hours (mean VAS difference: -12.7 mm) and delayed recurrent flares (HR: 0.18–0.36).
Efficacy correlates with IL-1β pathway inhibition, validated by biomarker normalization.